

NEWS RELEASE

SHELDON INWENTASH AND JOINT ACTOR ACQUIRE SECURITIES OF NIRVANA LIFE SCIENCES INC.

Toronto, Ontario, March 22, 2022 – Sheldon Inwentash (“Inwentash”) announces that through the completion of the previously announced acquisition (the “Acquisition”) of 1253766 B.C. Ltd. (formerly Nirvana Life Sciences Inc.) (the “Private Company”) by Nirvana Life Sciences Inc. (formerly Endocan Solutions Inc.) (“Nirvana” or the “Company”), Inwentash and ThreeD Capital Inc. (the “Joint Actor”) acquired ownership and control of an aggregate of 4,500,000 common shares of Nirvana in exchange for 4,500,000 common shares of the Private Company. As a result of the Acquisition, the percentage ownership held by Inwentash and the Joint Actor exceeded 10% of the issued and outstanding shares of the Company on a non-dilutive and partially dilutive basis.

Immediately prior to the Acquisition, Inwentash and the Joint Actor owned and controlled an aggregate of 4,500,000 common shares of the Private Company, representing approximately 17.3% of all issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis. Of this total, Inwentash held an aggregate 1,500,000 common shares of the Private Company, representing approximately 5.8% of the issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis. The Joint actor held an aggregate of 3,000,000 common shares of the Private Company, representing approximately 11.5% of the issued and outstanding common shares of the Private Company on a non-dilutive and partially dilutive basis.

Immediately following the Acquisition, Inwentash and the Joint Actor own and control an aggregate of 4,500,000 common shares of Nirvana, representing approximately 13.6% of all issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis. Of this total, Inwentash holds an aggregate of 1,500,000 common shares of the Company, representing approximately 4.5% of the issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis. The Joint Actor holds an aggregate of 3,000,000 common shares of the Company, representing approximately 9.1% of the issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis.

The holdings of securities of the Company by Inwentash and the Joint Actor are managed for investment purposes, and Inwentash or the Joint Actor could increase or decrease its investments in the Company at any time, or continue to maintain its current position, depending on market conditions or any other relevant factor.

The common shares of the Private Company were originally purchased through a private placement at a price of \$0.15 per Private Company common share for total proceeds paid of \$675,000.

Additional Information

A copy of the applicable securities report filed in connection with the matters set forth above may be obtained by contacting:

Sheldon Inwentash
130 Spadina Avenue, Suite 401
Toronto, ON
M5V 2L4

Tel: 416-941-8900